---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-25-000087"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2025-07-15T23:59:59+00:00"
generated_at: "2026-05-18T06:29:37.794678+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acumen Pharma enters Alzheimer's collaboration with JCR; up to $555M in milestones

## Summary
- JCR receives upfront payment (undisclosed) plus $9.25M option fee if Acumen exercises right to develop two candidates.
- Total milestones up to $555M ($40M development, $515M sales) plus single-digit royalties on sales.
- Leverages Acumen's amyloid beta oligomer antibodies and JCR's transferrin-receptor BBB technology for Alzheimer's.
- Company expects preclinical data package in early 2026 to support option exercise.

## SEC filing metadata
- accession: 0001576885-25-000087
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2025-07-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000087/0001576885-25-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000087/abos-20250715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-25-000087
- JSON: https://secwatch.observer/filing/0001576885-25-000087.json
- Plain text: https://secwatch.observer/filing/0001576885-25-000087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.